1Alpha,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats.
Diabetes mellitus is a major endocrine disorder and a growing health problem in most countries which can be ameliorated by numerous bio-molecules such as 1alpha,25 dihydroxyvitamin D3 [1alpha,25(OH)2VD3]. With this in mind, the current study investigated the therapeutic and preventive effects of 1alpha,25(OH)2VD3 on diabetes and its side effects: toxicity in liver, pancreas and kidneys. Our results show that administration of 1alpha,25(OH)2VD3 in diabetic rats increased the plasmatic insulin level, favored the normal blood glucose levels and normalized the hepatic glycogen concentration. In addition, 1alpha,25(OH)2VD3 enhanced superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX) (by 207, 52 and 72%, respectively) compared to diabetic rats. It also reduced lipid peroxidation and the indices of toxicity in liver and kidneys by significantly decreasing alkaline phosphatases (PAL), aspartate and lactate transaminase (AST and ALT) activities, total and direct bilirubin, triglycerides (TG), cholesterol, creatinine, urea and iron levels in diabetic rats. Moreover, the plasmatic non-enzymatic antioxidant level of HDL-cholesterol, magnesium (Mg), calcium (Ca) and copper (Cu) increased after 1alpha,25(OH)2VD3 administration. The administration of 1alpha,25(OH)2VD3 in diabetic rats protects against alloxan-induced histological changes in pancreas.


CONCLUSIONS
from these data, it is concluded that 1alpha,25(OH)2VD3 might be useful for the therapy and prevention of diabetes and the numerous side effects especially toxicity in liver, pancreas and kidneys and this protective effect is more obvious in our preventive experiment.
Hamden
Khaled
K
Laboratry of Animal Ecophysiology, Department of Life Science, Faculty of Science, University of Sfax, Tunisia. khaled.hamden@yahoo.fr
Carreau
Serge
S
Jamoussi
Kamel
K
Miladi
Slaheddine
S
Lajmi
Samiha
S
Aloulou
Dorra
D
Ayadi
Fatma
F
Elfeki
Abdelfattah
A
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002117:Calcitriol / Q000008:administration & dosage*; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism / Q000517:prevention & control*; D005979:Glutathione Peroxidase / Q000378:metabolism; D006003:Glycogen / Q000032:analysis; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000201:enzymology / Q000473:pathology; D007674:Kidney Diseases / Q000517:prevention & control*; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000201:enzymology / Q000473:pathology; D008107:Liver Diseases / Q000517:prevention & control*; D008297:Male; D009929:Organ Size; D018384:Oxidative Stress / Q000187:drug effects*; D010179:Pancreas; D010182:Pancreatic Diseases / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism
D001786:Blood Glucose; D007328:Insulin; D006003:Glycogen; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D002117:Calcitriol